08:00 , Dec 8, 2008 |  BioCentury  |  Emerging Company Profile

Verva: Fingerprinting diabetes solutions

Traditional drug discovery for diabetes has begun with identifying a target responsible for triggering a reversible step in the disease pathway, such as dipeptidyl peptidase-4 or peroxisome proliferation activated receptor . Rather than go after...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Company News

Adipogen Pharma, ChemGenex Pharmaceuticals cancer, metabolic news

CXS will spin out its metabolic disease unit, Autogen Research Pty. Ltd., which will merge with Adipogen and be renamed Verva Pharmaceuticals Ltd. CXS will focus on its cancer portfolio, including Ceflatonin homoharringtonine , a...
08:00 , Feb 17, 2003 |  BC Week In Review  |  Company News

Autogen, Merck KGaA deal

AGT received a E762,000 ($825,000) milestone from MRK under the companies' 2001 deal. AGT said the payment was triggered by additional data on AGT203, a gene that AGT said is involved in the two diseases....
07:00 , Apr 15, 2002 |  BioCentury  |  Strategy

Sequenom value chain

Sequenom value chain Target Target Lead Lead identification validation generation optimization MassARRAY system for genotyping and SNP analysis Functional assays (Autogen deal) Small molecules, peptide mimetics, medicinal chemistry(Provid deal) Structure-based drug design (Provid deal) DNA...
07:00 , Apr 15, 2002 |  BioCentury  |  Strategy

Sequenom reaches lead optimization

Sequenom Inc. 's latest deal marks a major step in its efforts to migrate downstream into products. In a collaboration announced last week, Provid Pharmaceuticals Inc. will provide medicinal and structure-based design technologies for developing...
07:00 , May 10, 1999 |  BC Week In Review  |  Company News

Autogen, Lipha s.a. deal

The companies entered into an R&D collaboration focused on obesity and diabetes combining AWI's molecular and gene technology with Lipha's diabetes expertise. Lipha, a subsidiary of Merck KgaA (Darmstadt, Germany), will provide research and milestone...